18 September 2020 - PHARMAC is pleased to announce a decision to fund an additional brand of budesonide with eformoterol inhaler (DuoResp Spiromax) for patients with asthma or COPD.

This decision means that people will have a choice of two different funded dry powder inhalers that contain budesonide with eformoterol. The Respiratory Procurement Advisory Group considered that this inhaler seemed easy to use, which was reiterated by some responders suggesting that this could be of benefit for patients who have lower levels of dexterity. This devices similarity to metered dose inhaler could be of benefit for certain patients who prefer this to the currently funded dry powder inhaler.

Patients would be able to change to this brand of budesonide with eformoterol dry powder inhaler at the pharmacy.

Read PHARMAC press release